These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25409416)

  • 1. In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer.
    Frik M; Martínez A; Elie BT; Gonzalo O; Ramírez de Mingo D; Sanaú M; Sánchez-Delgado R; Sadhukha T; Prabha S; Ramos JW; Marzo I; Contel M
    J Med Chem; 2014 Dec; 57(23):9995-10012. PubMed ID: 25409416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular Localization Studies of the Luminescent Analogue of an Anticancer Ruthenium Iminophosphorane with High Efficacy in a Triple-Negative Breast Cancer Mouse Model.
    Miachin K; Del Solar V; El Khoury E; Nayeem N; Khrystenko A; Appelt P; Neary MC; Buccella D; Contel M
    Inorg Chem; 2021 Dec; 60(24):19152-19164. PubMed ID: 34846878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells.
    Montani M; Pazmay GVB; Hysi A; Lupidi G; Pettinari R; Gambini V; Tilio M; Marchetti F; Pettinari C; Ferraro S; Iezzi M; Marchini C; Amici A
    Pharmacol Res; 2016 May; 107():282-290. PubMed ID: 27038531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the Effects and Mechanisms of Anticancer Action of a Ru(II)-Arene Iminophosphorane Compound in Triple Negative Breast Cancer Cells.
    Nayeem N; Yeasmin A; Cobos SN; Younes A; Hubbard K; Contel M
    ChemMedChem; 2021 Nov; 16(21):3280-3292. PubMed ID: 34329530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model.
    Mendes N; Tortosa F; Valente A; Marques F; Matos A; Morais TS; Tomaz AI; Gärtner F; Garcia MH
    Anticancer Agents Med Chem; 2017; 17(1):126-136. PubMed ID: 27671310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
    Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
    J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
    Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
    Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationally Designed Ruthenium Complexes for Breast Cancer Therapy.
    Golbaghi G; Castonguay A
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31936496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
    Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights.
    Lease N; Vasilevski V; Carreira M; de Almeida A; Sanaú M; Hirva P; Casini A; Contel M
    J Med Chem; 2013 Jul; 56(14):5806-18. PubMed ID: 23786413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
    Nardon C; Brustolin L; Fregona D
    Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
    Battistin F; Scaletti F; Balducci G; Pillozzi S; Arcangeli A; Messori L; Alessio E
    J Inorg Biochem; 2016 Jul; 160():180-8. PubMed ID: 26920229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amberlite IR-120 (H) mediated "on water" synthesis of fluorescent Ruthenium(II)-arene 8-hydroxyquinoline complexes for cancer therapy and live cell imaging.
    Mondal A; De S; Maiti S; Sarkar B; Sk AK; Jacob R; Moorthy A; Paira P
    J Photochem Photobiol B; 2018 Jan; 178():380-394. PubMed ID: 29195215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New water-soluble ruthenium(II) cytotoxic complex: biological activity and cellular distribution.
    Morais TS; Santos FC; Jorge TF; Côrte-Real L; Madeira PJ; Marques F; Robalo MP; Matos A; Santos I; Garcia MH
    J Inorg Biochem; 2014 Jan; 130():1-14. PubMed ID: 24145065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel ruthenium(II) triazine complex [Ru(bdpta)(tpy)]
    Purushothaman B; Arumugam P; Ju H; Kulsi G; Samson AAS; Song JM
    Eur J Med Chem; 2018 Aug; 156():747-759. PubMed ID: 30048924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Class of Half-Sandwich Ruthenium(II) Arene Complexes Bearing the Water-Soluble CAP Ligand as an in Vitro Anticancer Agent.
    Guerriero A; Oberhauser W; Riedel T; Peruzzini M; Dyson PJ; Gonsalvi L
    Inorg Chem; 2017 May; 56(10):5514-5518. PubMed ID: 28443659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes.
    Liu P; Jia J; Zhao Y; Wang KZ
    Mini Rev Med Chem; 2016; 16(4):272-89. PubMed ID: 26586123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transport of the Ruthenium Complex [Ru(GA)(dppe)
    Naves MA; Graminha AE; Vegas LC; Luna-Dulcey L; Honorato J; Menezes ACS; Batista AA; Cominetti MR
    Mol Pharm; 2019 Mar; 16(3):1167-1183. PubMed ID: 30633527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Water-Soluble Ruthenium(II) Complexes with Chiral 4-(2,3-Dihydroxypropyl)-formamide Oxoaporphine (FOA): In Vitro and in Vivo Anticancer Activity by Stabilization of G-Quadruplex DNA, Inhibition of Telomerase Activity, and Induction of Tumor Cell Apoptosis.
    Chen ZF; Qin QP; Qin JL; Zhou J; Li YL; Li N; Liu YC; Liang H
    J Med Chem; 2015 Jun; 58(11):4771-89. PubMed ID: 25988535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.
    Ferraro MG; Piccolo M; Misso G; Maione F; Montesarchio D; Caraglia M; Paduano L; Santamaria R; Irace C
    Cells; 2020 Jun; 9(6):. PubMed ID: 32517101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.